Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostWritten by Chris Markoch. Posted: 2/5/2026. 
Key Points - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion, and adjusted earnings per share (EPS) came in at $0.69 versus expectations of $0.57. The report also included positive topline results from the Phase 2b study of Pfizer's lead GLP-1 candidate. Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now PFE stock closed up about 4% on Feb. 4 as analysts and investors digested the results. The bullish case is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside likely stems from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That narrative begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is growing rapidly. One forecast shows the global GLP-1 market expanding from $62.2 billion in 2025 to $157 billion by 2035. That's a compound annual growth rate (CAGR) of about 9.7%, which helps explain why billions of dollars are flowing into the sector as companies race to capture market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. In the Phase 2b VESPER-3 study, the trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by week 28. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom credited the positive clinical data for the stock's gain. That may be true, but investors should recognize that such enthusiasm can be short-lived. Pfizer's GLP-1 candidate shows promise, but it will take time for that to meaningfully affect the company's top line. The GLP-1 trade is expanding, and large competitors such as Eli Lilly & Co. (NYSE: LLY) have entrenched leadership in obesity drugs and aren't stepping aside. There are, however, other reasons to be bullish on PFE—most notably its oncology portfolio. One estimate from Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, reflecting a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had around 60 candidates in its product portfolio—each representing an opportunity to capture share. The company's pipeline was materially enlarged by its acquisition of Seagen in 2023. Pfizer's development roster includes late-stage candidates such as Vepdegestrant, a next-generation targeted protein degrader (PROTAC), and atirmociclib, a selective CDK4 inhibitor, both aimed at ER+/HER2- metastatic breast cancer in later-stage trials. - Sigvotatug vedotin, an antibody-drug conjugate (ADC), is in Phase 3 testing (for example, Be6A LUNG-01) against metastatic non-small cell lung cancer, leveraging expertise acquired from Seagen.
- Sasanlimab is being evaluated for bladder cancer, while a bispecific PD-1xVEGF agent (PF-4404) is being studied in combination with Padcev to treat urothelial cancer—programs positioned to become blockbusters if successful.
Beyond the number of candidates, Pfizer's commitment to artificial intelligence (AI) adds another layer to the bullish case. AI is becoming essential to many companies in the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships with firms such as Boltz (biomolecular modeling), XtalPi (molecular design), and Data4Cure (oncology data analytics), and by using tools like OncoScout to speed target identification. Internally, platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) aim to optimize discovery and manufacturing. These efforts helped accelerate the development of Paxlovid and support 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains driven by AI and other tools. Industry-wide, AI is projected to boost productivity by roughly 35% to 45% by improving preclinical decision-making and trial design, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself at the forefront of these adoption efforts, which should benefit investors over the medium- and long-term.
| 
